Zacks: Can-Fite Biopharma Ltd (NASDAQ:CANF) Given Consensus Rating of “Strong Buy” by Brokerages

Can-Fite Biopharma Ltd (NASDAQ:CANF) has received an average broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus target price of $7.00 for the company, according to Zacks. Zacks has also given Can-Fite Biopharma an industry rank of 96 out of 255 based on the ratings given to its competitors.

Shares of NASDAQ CANF traded up $0.38 during trading hours on Wednesday, hitting $1.65. 5,736,973 shares of the stock were exchanged, compared to its average volume of 600,141. The company’s fifty day simple moving average is $2.40 and its two-hundred day simple moving average is $2.55. Can-Fite Biopharma has a 1-year low of $1.08 and a 1-year high of $24.30.

Can-Fite Biopharma (NASDAQ:CANF) last issued its earnings results on Friday, November 29th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.32). The business had revenue of $1.15 million for the quarter.

Can-Fite Biopharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

Recommended Story: How is the discount rate different from the Federal Funds rate?

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.